Novel strategies to eliminate persistent viral infections

Trends in Immunology

Volumn 29, Issue 3, 2008, Pages 116-124

  Martinic, Marianne M ^a   von Herrath, Matthias G ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR;

AUTOIMMUNE DISEASE; CELL FUNCTION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CHRONIC DISEASE; HUMANS; INTERLEUKIN-10; VIRUS DISEASES;

EID: 39749159661     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2007.12.002     Document Type: Review

References (90)

1. Katze M.G., et al. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2 (2002) 675-687
2. Doherty P.C., and Christensen J.P. Accessing complexity: the dynamics of virus-specific T cell responses. Annu. Rev. Immunol. 18 (2000) 561-592
3. Kaech S.M., et al. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2 (2002) 251-262
4. Moskophidis D., et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362 (1993) 758-761
5. Zajac A.J., et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188 (1998) 2205-2213
6. Wherry E.J., and Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78 (2004) 5535-5545
7. Klenerman P., and Hill A. T cells and viral persistence: lessons from diverse infections. Nat. Immunol. 6 (2005) 873-879
8. Ahmed R., et al. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160 (1984) 521-540
9. Zinkernagel R.M. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 263 (2002) 1-5
10. Krmpotic A., et al. Pathogenesis of murine cytomegalovirus infection. Microbes Infect. 5 (2003) 1263-1277
11. Doherty P.C., et al. Dissecting the host response to a γ-herpesvirus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356 (2001) 581-593
12. Sewell A.K., et al. Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape. Stem Cells 18 (2000) 230-244
13. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13 (1995) 29-60
14. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 (2005) 215-229
15. + cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr. Opin. Immunol. 13 (2001) 479-482
16. Moghaddam A., et al. An animal model for acute and persistent Epstein-Barr virus infection. Science 276 (1997) 2030-2033
17. Callan M.F. The immune response to Epstein-Barr virus. Microbes Infect. 6 (2004) 937-945
18. Coscoy L. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat. Rev. Immunol. 7 (2007) 391-401
19. Bangham C.R. HTLV-1 infections. J. Clin. Pathol. 53 (2000) 581-586
20. Finlay B.B., and McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124 (2006) 767-782
21. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
22. Day C.L., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006) 350-354
23. + T cells leads to reversible immune dysfunction. Nat. Med. 12 (2006) 1198-1202
24. + T cell survival in HIV infection. J. Exp. Med. 203 (2006) 2281-2292
25. Urbani S., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80 (2006) 11398-11403
26. + T lymphocytes in the liver. J. Immunol. 178 (2007) 2714-2720
27. Radziewicz H., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81 (2007) 2545-2553
28. + T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109 (2007) 4671-4678
29. Ejrnaes M., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203 (2006) 2461-2472
30. Brooks D.G., et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12 (2006) 1301-1309
31. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4 (2004) 336-347
32. Okazaki T., et al. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 14 (2002) 779-782
33. Iwai Y., et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198 (2003) 39-50
34. Ansari M.J., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198 (2003) 63-69
35. Liang S.C., et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33 (2003) 2706-2716
36. Salama A.D., et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198 (2003) 71-78
37. Brown J.A., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170 (2003) 1257-1266
38. Hori J., et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J. Immunol. 177 (2006) 5928-5935
39. Ishida M., et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84 (2002) 57-62
40. Yamazaki T., et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169 (2002) 5538-5545
41. Okazaki T., and Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27 (2006) 195-201
42. Sharpe A.H., et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8 (2007) 239-245
43. Latchman Y., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2 (2001) 261-268
44. Parry R.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25 (2005) 9543-9553
45. +) T cell effector functions after antigen recognition in the liver. Immunity 23 (2005) 53-63
46. Nishimura H., et al. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10 (1998) 1563-1572
47. Nishimura H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (1999) 141-151
48. Sauce D., et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 21 (2007) 2005-2013
49. Moore K.W., et al. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683-765
50. O'Garra A., and Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7 (2007) 425-428
51. Hawrylowicz C.M., and O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. 5 (2005) 271-283
52. Kuhn R., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
53. + T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. J. Immunol. 157 (1996) 798-805
54. Hsu D.H., et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250 (1990) 830-832
55. Maris C.H., et al. Interleukin-10 plays an early role in generating virus-specific T cell anergy. BMC Immunol. 8 (2007) 8
56. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189 (1999) 587-592
57. Pulendran B., et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1036-1041
58. Borrow P., et al. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J. Virol. 69 (1995) 1059-1070
59. Salvato M., et al. Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J. Virol. 65 (1991) 1863-1869
60. Cao W., et al. Identification of α-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282 (1998) 2079-2081
61. Sevilla N., et al. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192 (2000) 1249-1260
62. Kunz S., et al. Molecular analysis of the interaction of LCMV with its cellular receptor [α]-dystroglycan. J. Cell Biol. 155 (2001) 301-310
63. Sevilla N., et al. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J. Clin. Invest. 113 (2004) 737-745
64. +) T cell population in chronic hepatitis C virus infection. J. Clin. Invest. 113 (2004) 963-972
65. Rigopoulou E.I., et al. Blocking of interleukin-10 receptor-a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin. Immunol. 117 (2005) 57-64
66. Coombes J.L., et al. Regulatory T cells and intestinal homeostasis. Immunol. Rev. 204 (2005) 184-194
67. Reed C., and Daar E.S. Novel antiretroviral agents in HIV therapy. Curr. Infect. Dis. Rep. 8 (2006) 489-496
68. Dykxhoorn D.M., and Lieberman J. Silencing viral infection. PLoS Med. 3 (2006) e242
69. Brooks D.G., et al. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J. Clin. Invest. 116 (2006) 1675-1685
70. Gale Jr. M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945
71. Meylan E., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437 (2005) 1167-1172
72. Li X.D., et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17717-17722
73. Freundt E.C., and Lenardo M.J. Interfering with interferons: hepatitis C virus counters innate immunity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17539-17540
74. Lamarre D., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
75. Reiser M., et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41 (2005) 832-835
76. Matter M., et al. Elimination of chronic viral infection by blocking CD27 signaling. J. Exp. Med. 203 (2006) 2145-2155
77. Borst J., et al. CD27 and CD70 in T cell and B cell activation. Curr. Opin. Immunol. 17 (2005) 275-281
78. Akiba H., et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-κB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-κB-inducing kinase. J. Biol. Chem. 273 (1998) 13353-13358
79. Tesselaar K., et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat. Immunol. 4 (2003) 49-54
80. Bukczynski J., et al. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J. Immunol. 175 (2005) 6378-6389
81. + T regulatory cell inhibition. J. Immunol. 176 (2006) 2486-2495
82. + T cells upon acute versus persistent viral infection. Immunity 9 (1998) 449-457
83. MacDonald A.J., et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J. Infect. Dis. 185 (2002) 720-727
84. +) T cells by regulatory T cells during persistent retroviral infection. Immunity 20 (2004) 293-303
85. + T cells during chronic hepatitis C virus infection. J. Virol. 79 (2005) 7860-7867
86. + T cells during persistent hepatitis C virus infection. J. Virol. 79 (2005) 7852-7859
87. - regulatory T cells. J. Immunol. 176 (2006) 4748-4756
88. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3 (2003) 253-257
89. + Tregs and immune control. J. Clin. Invest. 114 (2004) 1209-1217
90. Sakaguchi S., and Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int. Rev. Immunol. 24 (2005) 211-226